UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): March 29, 2005



                               THERMOGENESIS CORP.
             (Exact name of registrant as specified in its charter)


     Delaware                      0-16375                    94-3018487
     ---------                     --------                   ----------
 (State or other           (Commission File Number)        (I.R.S. Employer
 jurisdiction of                                          Identification No.)
 incorporation or
 organization)
                                2711 Citrus Road
                        Rancho Cordova, California 95742
              (Address and telephone number of principal executive
                               offices) (Zip Code)

                                 (916) 858-5100
              (Registrant's telephone number, including area code)

Checkthe   appropriate  box  below  if  the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule
    14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))


<PAGE>



Section 1 - Registrant's Business and Operations
------------------------------------------------

Item 1.01 Entry into a Material Definitive Agreement
---------------------------------------------------

     On March 29,  2005,  ThermoGenesis  Corp.  (the  "Company")  entered into a
Supply Agreement with Cell Factors Technology,  Inc., an Indiana corporation and
an affiliate of Biomet, Inc. ("CFT") (the "Agreement"). Under the Agreement, the
Company will manufacture a Thrombin disposable and Reagent for the Clotalyst(TM)
system.  Clotalyst  is CFT's an  autologous  clotting  factor  device  and blood
processing  disposables.  The Company assumes the role of manufacture for CFT of
the  Clotalyst(TM)  device  and blood  processing  disposals  for a term of five
years.  The Agreement  requires CFT, upon FDA  clearance,  to purchase a minimum
quantity of 20,000  devices.  CFT will pay a onetime advance fee for engineering
and  development  of the product.  For more  information,  see the press release
attached as Exhibit 99 and Agreement attached as Exhibit 10.

Section 9 - Financial Statements and Exhibits
---------------------------------------------

Item 9.01 Financial Statements and Exhibits.
--------------------------------------------

     Exhibit No.                Exhibit Description
     -----------                -------------------
       10                       Supply Agreement of Clotalyst(TM) Thrombin
                                Product between ThermoGenesis Corp and Cell
                                Factors Technologies, Inc. dated March 29, 2005

       99                       Press release dated April 5, 2005, titled
                                "ThermoGenesis Corp. to Supply Autologous
                                Thrombin Kits to Biomet, Inc."




<PAGE>


                                    SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                             THERMOGENESIS CORP.,
                             a Delaware Corporation


Dated:  April 4, 2005        /s/ Renee Ruecker
                             --------------------------------------------
                             Renee Ruecker,
                             Chief Financial Officer


<PAGE>


                                  EXHIBIT INDEX
                                  -------------


     Exhibit No.                Description
     -----------                -----------

         10                     Supply Agreement of Clotalyst(TM) Thrombin
                                Product between ThermoGenesis Corp and Cell
                                Factors Technologies, Inc. dated March 29, 2005.

         99                     Press release dated April 5, 2005, titled
                                "ThermoGenesis Corp. to Supply Autologous
                                Thrombin Kits to Biomet, Inc."


<PAGE>


                                                                      EXHIBIT 99

                          [THERMOGENESIS LOGO OMITTED]

                          THERMOGENESIS CORP. TO SUPPLY
                    AUTOLOGOUS THROMBIN KITS TO BIOMET, INC.

          Agreement addresses the need for autologous clotting factors
               and reduces the risk of exposure to Bovine thrombin

RANCHO CORDOVA, California (April 5, 2005) -- THERMOGENESIS CORP. (Nasdaq: KOOL)
announced  today  that the  Company  and  Biomet,  Inc  (NASDAQ:  BMET)  reached
agreement  for  the  Company  to  supply   Biomet's   subsidiary,   Cell  Factor
Technologies,  Inc. (CFT) with disposable  kits that produce  stable,  activated
thrombin from the patients own blood in less than 30 minutes. Approximately $180
million of thrombin  annually is consumed  worldwide as a blood clotting  enzyme
that surgeons use for topical hemostasis, the treatment of pseudoaneurysms,  and
to form "platelet gels" for the treatment of damaged tissue.

Kevin  Simpson,  President & COO of  ThermoGenesis  noted,  "We are very excited
about our new  partnership  with  Biomet's  CFT  subsidiary  to address the many
potential   thrombin    applications   in   their   orthopedic,    neurosurgery,
maxilliofacial, and dental reconstructive markets. This novel disposable device,
based on our  technology  and patents,  allows  surgeons to treat  patients with
autologous  thrombin  (thrombin  manufactured from their own blood),  instead of
bovine thrombin that has been reported to cause adverse reactions in patients as
reported in 28 peer reviewed journal articles. In Europe and Japan, these health
risks and  additional  concerns  about "mad cow  disease"  have nearly ended the
clinical use of bovine thrombin.

Joel  Higgins,  Vice  President of Technical  Affairs for CFT,  commented,  "Our
agreement  with  ThermoGenesis  will provide a key product for our  customers to
create  the  highest  quality  and  safest  biological  solutions  for  enhanced
recovery.  This new  thrombin  device  will  enable our  Gravitational  Platelet
Separation System (GPS) system to provide a completely "autologous" platelet gel
that our  customers  are  currently  demanding.  We look forward to working with
ThermoGenesis to bring this device to market."

Regulatory  Status
------------------
An autologous  thrombin  disposable  device  manufactured  by
THERMOGENESIS  has received CE Mark approval from the European  Union  Competent
Authorities  and is being  sold in Europe by the  Biomet  subsidiary,  Interpore
International,  Inc. This newly configured  thrombin  disposable  device will be
marketed under the Biomet trademarked name,  ClotalystTM Thrombin Device, and is
expected to be submitted for CE Mark this year.  The  regulatory  pathway in the
United States is unclear and may require a Pre-Market  Approval  Application for
the platelet gel product of which the autologous thrombin is a component.

About Biomet Inc.
-----------------
Biomet,  Inc and its  subsidiaries  design,  manufacture  and
market products used primarily by  musculoskeletal  medical  specialists in both
surgical and non-surgical  therapy. The company's product portfolio  encompasses
reconstructive  products,  including orthopedic joint replacement devices,  bone
cements and accessories,  and dental reconstructive implants; fixation products,
including  electrical bone growth stimulators,  internal and external orthopedic
fixation devices,  craniomaxillofacial  implants and bone substitute  materials;
spinal  products,  including  spinal  stimulation  devices,  spinal hardware and
orthobiologics;  and other products,  such as arthroscopy products and softgoods
and  bracing  products.   Headquartered  in  Warsaw,  Indiana,  Biomet  and  its
subsidiaries currently distribute products in more than 100 countries.

About THERMOGENESIS CORP.
-------------------------
After extensive research, THERMOGENESIS CORP.'s newly introduced technology
platforms lead the world in their ability to produce biological products from
single units of blood. Umbilical cord blood banks are utilizing the Company's
BioArchive(R) System as a critical enabling technology for cryogenic archiving
of stem cells for transplant, while its CryoSeal FS System is used to prepare
hemostatic and adhesive surgical sealants from patient blood in about an hour.
THERMOGENESIS CORP. has been a leading supplier of state-of-the-art Ultra-Rapid
Blood Plasma Freezers and Thawers to hospitals and blood banks since 1992.

The  statements  contained in this release  which are not  historical  facts are
forward-looking  statements  that are  subject to risks and  uncertainties  that
could cause  actual  results to differ  materially  from those  expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company's  control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products, and other risks detailed
from time to time in the  Company's  filings  with the  Securities  and Exchange
Commission.

                           More Information, Contact:
                               THERMOGENESIS CORP.
                          Kevin Simpson: (916) 858-5100
[{"type": "8-K", "sequence": "1", "filename": "for8k032905.txt", "secsgml_size_bytes": 10154}]
{"company-data": {"conformed-name": "THERMOGENESIS CORP", "cik": "0000811212", "assigned-sic": "3821", "irs-number": "943018487", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "333-82900", "film-number": "05731344"}, "business-address": {"street1": "2711 CITRUS ROAD", "city": "RANCHO CORDOVA", "state": "CA", "zip": "95742", "phone": "9168585100"}, "mail-address": {"street1": "2711 CITRUS ROAD", "city": "RANCHO CORDOVA", "state": "CA", "zip": "95742"}, "former-company": {"former-conformed-name": "INSTA COOL INC OF NORTH AMERICA", "date-changed": "19920703"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): March 29, 2005

                               THERMOGENESIS CORP.
             (Exact name of registrant as specified in its charter)

     Delaware                      0-16375                    94-3018487
     ---------                     --------                   ----------
 (State or other           (Commission File Number)        (I.R.S. Employer
 jurisdiction of                                          Identification No.)
 incorporation or
 organization)
                                2711 Citrus Road
                        Rancho Cordova, California 95742
              (Address and telephone number of principal executive
                               offices) (Zip Code)

                                 (916) 858-5100
              (Registrant's telephone number, including area code)

Checkthe   appropriate  box  below  if  the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule
    14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))
Section 1 - Registrant's Business and Operations
------------------------------------------------

Item 1.01 Entry into a Material Definitive Agreement
---------------------------------------------------

     On March 29,  2005,  ThermoGenesis  Corp.  (the  "Company")  entered into a
Supply Agreement with Cell Factors Technology,  Inc., an Indiana corporation and
an affiliate of Biomet, Inc. ("CFT") (the "Agreement"). Under the Agreement, the
Company will manufacture a Thrombin disposable and Reagent for the Clotalyst(TM)
system.  Clotalyst  is CFT's an  autologous  clotting  factor  device  and blood
processing  disposables.  The Company assumes the role of manufacture for CFT of
the  Clotalyst(TM)  device  and blood  processing  disposals  for a term of five
years.  The Agreement  requires CFT, upon FDA  clearance,  to purchase a minimum
quantity of 20,000  devices.  CFT will pay a onetime advance fee for engineering
and  development  of the product.  For more  information,  see the press release
attached as Exhibit 99 and Agreement attached as Exhibit 10.

Section 9 - Financial Statements and Exhibits
---------------------------------------------

Item 9.01 Financial Statements and Exhibits.
--------------------------------------------

     Exhibit No.                Exhibit Description
     -----------                -------------------
       10                       Supply Agreement of Clotalyst(TM) Thrombin
                                Product between ThermoGenesis Corp and Cell
                                Factors Technologies, Inc. dated March 29, 2005

       99                       Press release dated April 5, 2005, titled
                                "ThermoGenesis Corp. to Supply Autologous
                                Thrombin Kits to Biomet, Inc."
SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                             THERMOGENESIS CORP.,
                             a Delaware Corporation

Dated:  April 4, 2005        /s/ Renee Ruecker
                             --------------------------------------------
                             Renee Ruecker,
                             Chief Financial Officer
EXHIBIT INDEX
                                  -------------

     Exhibit No.                Description
     -----------                -----------

         10                     Supply Agreement of Clotalyst(TM) Thrombin
                                Product between ThermoGenesis Corp and Cell
                                Factors Technologies, Inc. dated March 29, 2005.

         99                     Press release dated April 5, 2005, titled
                                "ThermoGenesis Corp. to Supply Autologous
                                Thrombin Kits to Biomet, Inc."
EXHIBIT 99

                          [THERMOGENESIS LOGO OMITTED]

                          THERMOGENESIS CORP. TO SUPPLY
                    AUTOLOGOUS THROMBIN KITS TO BIOMET, INC.

          Agreement addresses the need for autologous clotting factors
               and reduces the risk of exposure to Bovine thrombin

RANCHO CORDOVA, California (April 5, 2005) -- THERMOGENESIS CORP. (Nasdaq: KOOL)
announced  today  that the  Company  and  Biomet,  Inc  (NASDAQ:  BMET)  reached
agreement  for  the  Company  to  supply   Biomet's   subsidiary,   Cell  Factor
Technologies,  Inc. (CFT) with disposable  kits that produce  stable,  activated
thrombin from the patients own blood in less than 30 minutes. Approximately $180
million of thrombin  annually is consumed  worldwide as a blood clotting  enzyme
that surgeons use for topical hemostasis, the treatment of pseudoaneurysms,  and
to form "platelet gels" for the treatment of damaged tissue.

Kevin  Simpson,  President & COO of  ThermoGenesis  noted,  "We are very excited
about our new  partnership  with  Biomet's  CFT  subsidiary  to address the many
potential   thrombin    applications   in   their   orthopedic,    neurosurgery,
maxilliofacial, and dental reconstructive markets. This novel disposable device,
based on our  technology  and patents,  allows  surgeons to treat  patients with
autologous  thrombin  (thrombin  manufactured from their own blood),  instead of
bovine thrombin that has been reported to cause adverse reactions in patients as
reported in 28 peer reviewed journal articles. In Europe and Japan, these health
risks and  additional  concerns  about "mad cow  disease"  have nearly ended the
clinical use of bovine thrombin.

Joel  Higgins,  Vice  President of Technical  Affairs for CFT,  commented,  "Our
agreement  with  ThermoGenesis  will provide a key product for our  customers to
create  the  highest  quality  and  safest  biological  solutions  for  enhanced
recovery.  This new  thrombin  device  will  enable our  Gravitational  Platelet
Separation System (GPS) system to provide a completely "autologous" platelet gel
that our  customers  are  currently  demanding.  We look forward to working with
ThermoGenesis to bring this device to market."

Regulatory  Status
------------------
An autologous  thrombin  disposable  device  manufactured  by
THERMOGENESIS  has received CE Mark approval from the European  Union  Competent
Authorities  and is being  sold in Europe by the  Biomet  subsidiary,  Interpore
International,  Inc. This newly configured  thrombin  disposable  device will be
marketed under the Biomet trademarked name,  ClotalystTM Thrombin Device, and is
expected to be submitted for CE Mark this year.  The  regulatory  pathway in the
United States is unclear and may require a Pre-Market  Approval  Application for
the platelet gel product of which the autologous thrombin is a component.

About Biomet Inc.
-----------------
Biomet,  Inc and its  subsidiaries  design,  manufacture  and
market products used primarily by  musculoskeletal  medical  specialists in both
surgical and non-surgical  therapy. The company's product portfolio  encompasses
reconstructive  products,  including orthopedic joint replacement devices,  bone
cements and accessories,  and dental reconstructive implants; fixation products,
including  electrical bone growth stimulators,  internal and external orthopedic
fixation devices,  craniomaxillofacial  implants and bone substitute  materials;
spinal  products,  including  spinal  stimulation  devices,  spinal hardware and
orthobiologics;  and other products,  such as arthroscopy products and softgoods
and  bracing  products.   Headquartered  in  Warsaw,  Indiana,  Biomet  and  its
subsidiaries currently distribute products in more than 100 countries.

About THERMOGENESIS CORP.
-------------------------
After extensive research, THERMOGENESIS CORP.'s newly introduced technology
platforms lead the world in their ability to produce biological products from
single units of blood. Umbilical cord blood banks are utilizing the Company's
BioArchive(R) System as a critical enabling technology for cryogenic archiving
of stem cells for transplant, while its CryoSeal FS System is used to prepare
hemostatic and adhesive surgical sealants from patient blood in about an hour.
THERMOGENESIS CORP. has been a leading supplier of state-of-the-art Ultra-Rapid
Blood Plasma Freezers and Thawers to hospitals and blood banks since 1992.

The  statements  contained in this release  which are not  historical  facts are
forward-looking  statements  that are  subject to risks and  uncertainties  that
could cause  actual  results to differ  materially  from those  expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company's  control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products, and other risks detailed
from time to time in the  Company's  filings  with the  Securities  and Exchange
Commission.

                           More Information, Contact:
                               THERMOGENESIS CORP.
                          Kevin Simpson: (916) 858-5100